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Aim: This manuscript reviews the English language literature on the use of intensity mod-
ulated radiation therapy (IMRT) for gynecologic malignancies, focusing on the treatment
cervical cancer.
Background: Radiation therapy plays a key role in both deﬁnitive and adjuvant treatment of
these patients, although efforts continue to minimize acute and chronic toxicity. IMRT  is an
attractive option because of the potential to dose escalate to the target while sparing organs
at  risk.
Methods and Materials: The English language literature was reviewed for relevant studies.
Results: Multiple heterogeneous studies have showed dosimetric and clinical beneﬁts with
reduction in acute and late gastrointestinal, genitourinary and hematologic toxicity, espe-
cially in the post hysterectomy scenario and for dose escalation to para-aortic nodes.
Consensus is evolving regarding necessary margins and target delineation in the context
of  organ movement and tumor shrinkage during the course of radiotherapy. Protocols withdaily soft-tissue visualization are being investigated.
Conclusions: Consistency in approach and reporting are vital in order to acquire the data to
justify the considerable increased expense of IMRT.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
radio-chemotherapy is the standard of care. Phase III ran-.  Introduction
ntensity modulated radiation therapy (IMRT) is an external
eam modality which uses variable intensity across the face of
he beam to shape isodoses to achieve a high tumor dose while
inimizing exposure to healthy tissue. The combination of 3D
lanning and variable radiation intensity in each ﬁeld provides
osimetric advantages which have been exploited in a variety
f pathologic sites including cancer of the cervix.
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Cervix cancer management varies depending on the FIGO
stage, but radiotherapy plays a vital role across the range
of presentations. For early stages, treatment may consist of
surgery or radiotherapy alone, but in the presence of adverse
prognostic factors, surgery will be combined with radiothe-
rapy. For bulky or locally advanced presentations, combineddomized trials showing the beneﬁt of concurrent cisplatinum
with pelvic radiotherapy also provide toxicity data. Acute
and chronic grade 3–4 gastrointestinal toxicity is 7–16% and
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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genitourinary up to 17%.1–6 These toxicity rates increase
when radiation ﬁelds are extended to include the para-aortic
regions, with grade 3–4 acute gastrointestinal toxicity in up to
49% and chronic toxicity seen in up to 34% at 36 months. Grade
3 or 4 hematologic toxicity is reported in 76%.1,7,8 RTOG 0116
combined chemotherapy and extended ﬁeld radiotherapy, and
found acute nonhematologic grade 3–4 toxicity of 81%, and
chronic grade 3–4 toxicity of 40% with follow up ranging to 38
months.7
Follow up is relatively short in many  of these studies, and
despite the already high toxicity, the situation may worsen
with time. Two decades ago, Eifel et al. reported that the risk of
serious complications from radiotherapy increases with time
but at different rates depending on the organ system studied.
Retrospective analysis was performed on 1784 patients with
carcinoma of the cervix treated with radiation. Grade 3 toxicity
levels at 3 and 5 years were 7.7 and 9.3% but increased approx-
imately 0.34% per year through 10–20 years. Although most
serious complications are diagnosed within 2–3 years, the risk
continues to increase steadily up to 25 years after treatment,
especially in the genitourinary system. This underlines the
need for improvement in radiotherapy delivery.9
2.  Dosimetric  beneﬁts  of  IMRT
Early work on IMRT  showed advantages compared to 3D
conformal radiotherapy in dose reduction to the organs at
risk for radiation toxicity.10–13,14 Roeske et al. compared the
dose received by the small bowel, bladder and rectum in ten
patients with gynecologic cancers treated with either 3D con-
formal or IMRT.  The V100 of the small bowel was reduced by
50% (p = 0.0005) and the V100 of the rectum and bladder by 23%
(p = 0.0002 and p = 0.0005 respectively).13 When IMRT  is used to
deliver a 20–30 Gy boost, Chan et al. found a signiﬁcant reduc-
tion in high dose volumes in 12 patients with cancer of the
cervix, vagina or endometrium compared to the use of 3D con-
formal or a 4 ﬁeld box. The V66 of the rectum was reduced by
22% (p < 0.001) and the bladder by 19% (p < 0.001).15
Mell et al. reported the dose volume histograms for organs-
at-risk for 7 patients with carcinoma of the cervix treated
with chemotherapy concurrent with IMRT,  3D conformal, or
an anterior-posterior parallel opposed pair and found that
dose to the bone marrow and small bowel was reduced, but
the reduction to the rectum and bladder was less impressive.
Hematologic tolerance was improved with less grade 3–4 tox-
icity by reducing low-dose irradiation to the bone marrow; V20
was 99, 97.8 and 72% with AP-PA, 4-Field box, and Bone marrow
sparing -IMRT.16 The question of how much dose reduction is
required, and to what volume, has not been answered. Simp-
son et al. suggested that a decrease in the V45 of the small
bowel by 100 cc reduced grade 2 toxicity by 50% 17. Mell et al.
found a correlation between hematologic toxicity and the vol-
ume of pelvic bone marrow receiving 10–20 Gy.16 This has been
conﬁrmed by more  recent studies.18,193.  Impact  on  toxicity
The dosimetric advantages of IMRT  have resulted in reduc-
tion of both acute and chronic GI and GU toxicity.12,20,21–25iotherapy 1 8 ( 2 0 1 3 ) 363–370
Early retrospective studies by Mundt et al.12,23 showed a sig-
niﬁcant decrease in acute grade 2 GU toxicity from 91 to 60%,
and chronic GI toxicity from 20 to 3% with the use of IMRT
rather than a 4-ﬁeld box. Efforts to demonstrate superiority
of IMRT over 3D conformal have produced preliminary data
from many  small retrospective studies with short follow up
and including a heterogeneous mixture of deﬁnitive radiothe-
rapy and post-operative patients. Doses range from 45 to 60 Gy
with either pelvic or extended ﬁelds, and boosts are a mixture
of brachytherapy, IMRT, or an integrated IMRT  boost. Table 1
summarizes the retrospective data on toxicity.25
Evidence suggests that IMRT can spare bone marrow16,26
but given the large volume of hematopoietically active mar-
row in the pelvis and lower lumbar spine, speciﬁc planning
constraints are required. Otherwise, IMRT fails to show a clear
advantage over 3D conformal, with hematologic grade 3 tox-
icity of 28%21 for extended ﬁeld and 24% for pelvic ﬁelds.20
Regarding efﬁcacy (Table 2), no randomized comparisons
of IMRT  to other radiotherapy techniques exist but local fail-
ure rates, and overall and disease free survival appear to be
similar for IMRT compared to 3D conformal. Haselle et al.,
reported on 111 cervix cancer patients with a median follow
up of 27 months, treated with surgery or IMRT with or with-
out brachytherapy. Overall survival at 3 years was 78% and
disease free survival 69%.22 Zhang et al. included only post sur-
gical patients and consequently had only a 3.4% local regional
recurrence but a 27% metastatic failure rate.24 Overall survival
at 3 years was 71% and disease free survival 66%. The most
common site of failure was distant, an event that can only be
reduced by improved systemic therapy.
4.  IMRT  planning
Traditional external beam radiotherapy is based on ﬁeld lim-
its determined by bony landmarks. Large treatment volumes
include generous amounts of healthy tissue but margins of
security are large, such that target motion or change in GTV
during treatment are not issues. In the era of conformal treat-
ment with steep dose gradients, deﬁnition of the GTV and CTV
become crucial. Major uncertainties exist regarding IMRT  for
cervix cancer in determining the required margins, the accept-
able degree of homogeneity and the appropriate dose limits
for the organs at risk. Such contouring demands a thorough
knowledge of radiologic anatomy. Current RTOG protocols
using IMRT include a contouring atlas for pelvic volumes and
guidelines for dosimetric constraints.
Lim et al. published treatment guidelines for the radical
treatment of cervix cancer based on studies of postopera-
tive patients to create a consensus for the CTV and PTV of
the primary tumor and regional nodes. There was moderate
agreement on the contours of the cervix, uterus, vagina and
parametria, but determination of margins was difﬁcult given
that these structures are subject to movement, deformation
and tumor regression during treatment. There was lack of
agreement on the parametrial limits, the length of vagina to
be included in the PTV, and whether or not to include the
entire uterus. Individual variation amongst patients makes
the dynamic unpredictable. Margins of 1.5–2 cm around the
tumor CTV and 7 mm around the PTV were suggested, but only
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Table 1 – Retrospective studies on toxicity comparing IMRT  to other RT techniques.
Author/year n Patients Technique Field Planning target volume Dose Follow-up (median) Acute toxicity Chronic toxicity p-Value
Mundt 200212 40 Cervix/Endoa EBRT 4Fb vs IMRTc Pelvic CTVd + 1 cm 45 Gy NS GIe gr2: 60%
GUf gr2 10%
No G3
na  p = 0.002
p = 0.22
Reduced
ToxgG2 for
IMRT vs EBRT
4F
Mundt 200323 36 Cervix/Endo
I-II 70% RT
Adjuvant
EBRT  4F vs IMRT Pelvic CTV + 1 cm 45 Gy 19 m N/A GI 19% grade
not speciﬁed
p  = 0.001
Reduced Tox
compared to
3Dch
Chen 200711 68 Cervix
RT Adjuvant
EBRT4F vs IMRT+ CTi Pelvic na 50.4 Gy 14 m GI 1–2 36%
GU 1–2 30%
GI 6% GU 9% p < 0.05, but
Late Tox GU
p = 0.231
Beriwal 200721 36 Cervix RT
Adjuvant
Ib2-IVa
IMRT+ HDR-BTj + CT Pelvic + parak CTV
0.5 + 1 cm
45  Gy 18 m GI gr 3:3%
GU gr 3:3%
GU 3%
Grade ≥3
2y-actuarial
10%
Kidd 201025 452 Cervix Ia-IVb PET-CT
guided IMRT+ HDR vs
RTC3D + HDR/LDRl + CT
PET positive
para,
pelvic + para
CTV +7 mm 50.4 Gy 52 m NA G3 GU or GI
IMRT 6%
3Dc 17%
p  = 0.0017
Chen 201120 109 Cervix
IB2-IVA
IMRT + BT + CT Pelvic CTV + 0.7–1 cm 50.4–54 Gy 32 m GI 3:3% GI 4.5%
Hasselle 201122 111 Cervix I-IVA
Radical and
Adjuvant
IMRT  + HDR − BT CT Pelvic CTV + 0.7–1 cm 45 Gy 27 m Grade ≥3 2% Late tox
g > = 3:7%
Zhang 201224 58 Cervix I-II
Adjuvant
IMRT + QT Pelvic + Para CTV +1CM 50.4 Gy 34 m GU/GI G3 tox
5%
RTOG toxicity
G3 5.1%
a Endometrium.
b External beam radiotherapy 4 ﬁelds.
c Intensity modulated radiation therapy.
d Clinical target volume.
e Gastrointestinal.
f Genitourinary.
g Toxicity.
h Radiotherapy conformal 3D.
i Chemotherapy.
j High dose rate brachytherapy.
k Paraortic ﬁeld.
l Low dose rate brachytherapy.
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with daily soft tissue visualization for position veriﬁcation. If
bony landmarks are used for set-up, then margins must be
more  generous.27
Several studies have shown the importance of cervical
tumor regression during treatment, with a median volume
reduction of 46% (range: 6–100%).14,28 This suggests that IMRT
should be replanned during the ﬁnal third of treatment to take
advantage of the shrinking GTV. However, the reduction in the
CTV and PTV may be disproportionally small. Van de Bunt et al.
imaged 14 patients with MRI during treatment and reported
that when GTV reduction exceeded 30 cc, re-planning reduced
the small bowel in the high dose volume signiﬁcantly. Margins
of 10–15 mm were acceptable.14 Similarly, Lim et al. conﬁrmed
that DVH’s did not accurately reﬂect the actual dose received
by the target and organs at risk due to reduction in the GTV  of
48–96% and CTV of 8–77% in 20 patients imaged weekly with
MRI. He compared 3 IMRT  plans with different margins and
concluded that a margin of 5 mm may be adequate provided
daily soft tissue visualization was used for treatment set up.27
In addition to tumor regression, cervical-utero movement
is also an issue in IMRT delivery. Margins for this mobile tar-
get are at variance with those required for the relatively ﬁxed
nodal CTV. Taylor et al. imaged 33 patients with gynecologic
cancer using MRI and conﬁrmed that since the uterus is more
mobile than the cervix, asymmetric margins may be more
appropriate.29 Gordon et al. looked at 3 different dynamic
models for the utero-cervical unit and concluded that the
uterus would be under-dosed if margins were chosen based on
cervical movement.30 The bladder, rectum and small bowel are
also dynamic mobile structures that effect the position of the
GTV.31–33 Protocols requiring a full bladder and empty rectum
can minimize utero-cervical movement; such requirements
are included in recent RTOG protocols.34 The development of
individualized strategies is essential due to the large variation
within and between fractions for each patient. New protocols
are being tested based on imaging techniques that deal with
the variation in these structures during treatment, such as
MRI, bladder ultrasound and CT.31–33
Aside from under-dosing the target because of organ move-
ment, tumor regression and inaccurate contouring, there are
other signiﬁcant risks to take into consideration with IMRT.
Due to the multiplicity of ﬁelds and delivery angles, the inte-
gral dose to the patient is much higher than with other
techniques (Fig. 1). Studies such as MEII08 suggest that the vol-
ume of healthy tissue such as the small intestine, rectum and
bladder receiving a very low dose of radiation was higher with
IMRT.16 This may lead to development of radiation induced
malignancy.35–37
5.  IMRT  and  its  impact  on  resources
The complexity of IMRT results in greater consumption of
resources compared to traditional radiation techniques. The
time required for physicist and oncologist to complete con-
touring tasks and treatment planning is much greater due
to the detail required in contouring and the number of
ﬁelds employed. To minimize positioning errors, immobiliza-
tion must be certain and precise, and therapists take longer
to position patients. IMRT demands more  expensive and
reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) 363–370 367
Fig. 1 – Comparison of nodal boost plans, with respect to integral dose to the patient and the volume of tissue receiving low
l n. (c)
i
s
t
c
pevel radiation. (a) Parallel opposed pair plan. (b) 4-FIELD pla
sodose in plan c.ophisticated planning systems, quality control and main-
enance protocols. Recent analyses of cost effectiveness
omparing IMRT  with 3D conformal for tumor sites such as
rostate and head and neck have shown that the use of IMRT IMRT plan. Note the extensive volume enclosed by the 30%for prostate cancer in the United States increased the cost for
each quality adjusted life year saved by $50,000 compared 3D
conformal.38,39 In Canada, the increased expense is $27,800
over alternative techniques. In Spain IMRT  costs 5–6 times
d rad
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more  than 3D conformal. The variation between countries
depends on health care billing practices and the details of how
IMRT  is performed.
6.  The  current  role  of  IMRT
Dose escalation to the pelvis and para-aortic region with con-
ventional radiotherapy is prohibited by unacceptable toxicity.8
The dosimetric beneﬁts of IMRT  have been concentrated in
delivering a boost to these regions or a central boost to patients
not suitable for brachytherapy. Simultaneous boosts to the tar-
get or affected lymph nodes have shown good results and
the altered fractionation of a simultaneous boost has the
advantage of shortening treatment time and improving the
therapeutic ratio.15,40
At present the role and potential beneﬁts of IMRT have
been best established in the setting of post operative treat-
ment thanks to the ﬁndings of RTOG 0418.34 In 2008 Small et al.
published guidelines for contouring post operative patients
to establish consistency of reporting amongst institutions for
ease of comparison of data.41 Preliminary results from indi-
vidual institutions have shown a beneﬁt for these guidelines
for both early stage disease as well as for those with positive
nodes.11,24,42 The advantage of IMRT  for sparing of bone mar-
row in patients treated for pelvic tumors are being achieved
by identifying speciﬁcally the active marrow in the treatment
ﬁeld using PET, MRI  or SPECT. Early results are promising.43–45
7.  Future  directions
Improvements in toxicity allow evaluation of more  aggressive
treatment approaches. Duen˜as Gonzalez has reported good
results with more  radical chemotherapy in locally advanced
cervix cancer.46
One of the more  important advances in the last decade
has been identiﬁcation of genetic variability in the individual
response to radiotherapy through genetic markers of radiation
toxicity. Single nucleotide polymorphisms (SNP’s) are varia-
tions in the gene sequence that effect a single base pair and
appear in at least 1% of the population. There are 11.8 mil-
lion SNP’s registered in the NCBI genome data base. Numerous
studies are focusing on phenotypes susceptible to cancer and
to radiation toxicity. Phenotypic expression is complex and is
inﬂuenced by many  life style and environmental factors. There
are not yet any consistent associations between certain SNP’s
and types of radiation toxicity, possibly because of the great
number of treatment variables that are also known to inﬂu-
ence toxicity, such as the type of radiation, dose, treatment
volume, fractionation and use of concurrent chemotherapy.
Research in this area is just beginning.47
8.  Conclusions
IMRT  offers dosimetric advantages in organ sparing compared
with traditional 2D or 3D radiotherapy in treatment of cancer
of the cervix. This has maintained excellent long term cure
rates while reducing GI, GU and hematologic toxicity, espe-
cially in patients treated with concurrent chemotherapy. IMRTiotherapy 1 8 ( 2 0 1 3 ) 363–370
has made possible safer dose escalation to the para-aortic
region, or bulky GTV in patients nor suitable for brachyther-
apy. However, these results should be taken with some caution
given the heterogeneity of the populations studied, the small
numbers of patients, short follow up and great variability
in margins, treatment ﬁelds and dose prescription. A multi
center study has shown that the use of IMRT  for postopera-
tive cases is reliable, but a clear consensus is still lacking for
the delivery of radical treatment. Recommendations for con-
touring of volumes and the required margins continue to be
debated, given the inherent complexity of the pelvic dynamic,
the movement  and regression of the tumor and variable size
and position of the neighboring organs. In addition to con-
touring and planning issues, daily treatment veriﬁcation must
include soft tissue imaging to ensure correct alignment on the
target.
IMRT is a high complex modality with an inﬁnite num-
ber of planning options regarding the number of ﬁelds and
angles of incidence to cover the required volumes and to
meet the dose restrictions for the organs at risk. The result
is both a ﬂexible and powerful tool but one which consumes
vast resources in terms of physics, physicians, therapists and
machine time. Further prospective multi center trials will
provide the required data on disease control, toxicity and qual-
ity of life to fully integrate IMRT into the management of
cervical cancer.
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